retatrutide triple agonist phase 2 obesity trial glp-1 gip glucagon nejm 2023 Medscape Lilly's triple agonist, retatrutide, delivered

Endocrinology 153(2):647658 Mietlicki-Baase EG et al (2013) The food intake-suppressive effects of glucagon-like peptide-1 receptor signaling in the ventral tegmental area are mediated by AMPA/kainate receptors

The 12 mg dose produced a mean weight change of negative 23.7%, translating to roughly 60 pounds of weight loss

Takakura Y, Masuda S, Tokuda H, Nishikawa M, Hashida M

Strategic dose titration The clinical trial protocol starts at 1mg weekly and escalates every 4 weeks through 2mg, 4mg, 8mg, and potentially 12mg

A mechanism for regulated insulin delivery to the brain

But the fundamental principles wont change